Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients

BackgroundThe presence of circulating tumor cells (CTC) in the peripheral blood of cancer patients has been described for various solid tumors and their clinical relevance has been shown. CTC detection based on the analysis of epithelial antigens might be hampered by the genetic heterogeneity of the primary tumor and loss of epithelial antigens. Therefore, we aimed to identify new gene markers for the PCR-based detection of CTC in female cancer patients.MethodsGene expression of 38 cancer cell lines (breast, ovarian, cervical and endometrial) and of 10 peripheral blood mononuclear cell (PBMC) samples from healthy female donors was measured using microarray technology (Applied Biosystems). Differentially expressed genes were identified using the maxT test and the 50% one-sided trimmed maxT-test. Confirmatory RT-qPCR was performed for 380 gene targets using the AB TaqMan® Low Density Arrays. Then, 93 gene targets were analyzed using the same RT-qPCR platform in tumor tissues of 126 patients with primary breast, ovarian or endometrial cancer. Finally, blood samples from 26 healthy women and from 125 patients (primary breast, ovarian, cervical, or endometrial cancer, and advanced breast cancer) were analyzed following OncoQuick enrichment and RNA pre-amplification. Likewise, hMAM and EpCAM gene expression was analyzed in the blood of breast and ovarian cancer patients. For each gene, a cut-off threshold value was set at three standard deviations from the mean expression level of the healthy controls to identify potential markers for CTC detection.ResultsSix genes were over-expressed in blood samples from 81% of patients with advanced and 29% of patients with primary breast cancer. EpCAM gene expression was detected in 19% and 5% of patients, respectively, whereas hMAM gene expression was observed in the advanced group (39%) only. Multimarker analysis using the new six gene panel positively identified 44% of the cervical, 64% of the endometrial and 19% of the ovarian cancer patients.ConclusionsThe panel of six genes was found superior to EpCAM and hMAM for the detection of circulating tumor cells in the blood of breast cancer, and they may serve as potential markers for CTC derived from endometrial, cervical, and ovarian cancers.

[1]  P. Paterlini-Bréchot,et al.  Circulating tumor cells (CTC) detection: clinical impact and future directions. , 2007, Cancer letters.

[2]  Yongchao Ge.  Resampling-based Multiple Testing for Microarray Data Analysis , 2003 .

[3]  Mieke Schutte,et al.  Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.

[4]  I. Vlachonikolis,et al.  Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. , 2003, Anticancer research.

[5]  Kristine R Broglio,et al.  Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. , 2007, Clinical breast cancer.

[6]  T. Fehm,et al.  Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. , 2007, Gynecologic oncology.

[7]  Thomas Rau,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[8]  D. Hayes,et al.  The measurement and therapeutic implications of circulating tumour cells in breast cancer , 2005, British Journal of Cancer.

[9]  M. Kawai,et al.  Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. , 2001, Gynecologic oncology.

[10]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[11]  M. Lacroix,et al.  Significance, detection and markers of disseminated breast cancer cells. , 2006, Endocrine-related cancer.

[12]  C Hollmann,et al.  DETECTION OF DISSEMINATED TUMOR CELLS IN PERIPHERAL BLOOD , 2005, Critical reviews in clinical laboratory sciences.

[13]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[14]  W. Gillanders,et al.  Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: Interim results of a prospective cohort study , 2008, BMC Cancer.

[15]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[16]  T. Fujimoto,et al.  Real-time quantitative RT-PCR detection of disseminated endometrial tumor cells in peripheral blood and lymph nodes using the LightCycler System. , 2006, Gynecologic oncology.

[17]  Medical devices; immunology and microbiology devices; classification of the immunomagnetic circulating cancer cell selection and enumeration system. Final rule. , 2004, Federal register.

[18]  S. Knuutila,et al.  DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. , 1998, The American journal of pathology.

[19]  Paul Perco,et al.  Adaptive trimmed t‐statistics for identifying predominantly high expression in a microarray experiment , 2011, Statistics in medicine.

[20]  O. Kallioniemi,et al.  Genome screening by comparative genomic hybridization. , 1997, Trends in genetics : TIG.

[21]  A. Zaniboni,et al.  Molecular signature detection of circulating tumor cells using a panel of selected genes. , 2008, Cancer letters.

[22]  R. Zeillinger,et al.  Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. , 2010, Cancer letters.

[23]  J. Rosai,et al.  Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood. , 2005, Journal of experimental & clinical cancer research : CR.

[24]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  V. Georgoulias,et al.  Quantitative RT-PCR luminometric hybridization assay with an RNA internal standard for cytokeratin-19 mRNA in peripheral blood of patients with breast cancer. , 2001, Clinical biochemistry.

[26]  C. Tropé,et al.  Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis , 2002, Cancer.

[27]  Rudolf M. Huber,et al.  Combined transcriptome and genome analysis of single micrometastatic cells , 2002, Nature Biotechnology.

[28]  G. Bastert,et al.  Evaluating GA733-2 mRNA as a marker for the detection of micrometastatic breast cancer in peripheral blood and bone marrow , 1999, Archives of Gynecology and Obstetrics.

[29]  W. Reith,et al.  Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle , 1998, Oncogene.